title: A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice.
abstract: Using vanadyl sulphate, sodium orthovanadate or bis(maltolato)oxovanadium (BMOV), Cruz TF, Morgan A, Min W (1995, Mol Cell Biochem 153: 161-166) have recently demonstrated the antineoplastic effects of vanadium in mice. In this study, the antineoplastic effects of BMOV against human tumour cell lines was confirmed, and this effect was shown to depend on the prolonged exposure of the cells to the drug. We have investigated a polymeric drug delivery system for the sustained delivery of BMOV as an antineoplastic agent in mice. The objective was to design and evaluate an injectable polymer-BMOV paste that would act as a drug implant for the slow but sustained release of BMOV in the mice. In vitro studies showed that the biodegradable polymer poly (Ghlr epsilon epsilon-caprolactone) (PCL) released BMOV in a sustained manner with rates of drug release increasing with increased loading of the drug in the polymer. In vivo studies showed that PCL-BMOV paste implants produced a concentration-dependent inhibition of MDAY-D2 tumour growth via systemic drug delivery. Further in vivo studies showed that 5% BMOV-loaded PCL (containing 20% methoxypolyethylene glycol) was effective in preventing tumour regrowth of resected RIF tumour masses in mice when the PCL-BMOV paste was applied to the resected site for localized drug delivery. The results confirm the potential of vanadium as an antineoplastic agent and show that the injectable PCL-BMOV formulation releases a chemotherapeutic dose of vanadium for the systemic treatment of whole tumours as well as the localized treatment of resected RIF tumours.
authors.affiliation: Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
authors.forename: J K
authors.initials: JK
authors.lastname: Jackson
authors.forename: W
authors.initials: W
authors.lastname: Min
authors.forename: T F
authors.initials: TF
authors.lastname: Cruz
authors.forename: S
authors.initials: S
authors.lastname: Cindric
authors.forename: L
authors.initials: L
authors.lastname: Arsenault
authors.forename: D D
authors.initials: DD
authors.lastname: Von Hoff
authors.forename: D
authors.initials: D
authors.lastname: Degan
authors.forename: W L
authors.initials: WL
authors.lastname: Hunter
authors.forename: H M
authors.initials: HM
authors.lastname: Burt
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008811:Mice, Inbred DBA; D008855:Microscopy, Electron, Scanning; D011091:Polyesters / Q000008:administration & dosage*; D011753:Pyrones / Q000008:administration & dosage* / Q000737:chemistry; D012995:Solubility; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014638:Vanadates / Q000008:administration & dosage* / Q000737:chemistry
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D011091:Polyesters; D011753:Pyrones; C016240:polycaprolactone; C074212:bis(maltolato)oxovanadium(IV); D014638:Vanadates